InvestorsHub Logo
Followers 14
Posts 603
Boards Moderated 0
Alias Born 12/27/2017

Re: None

Tuesday, 04/16/2019 12:26:54 PM

Tuesday, April 16, 2019 12:26:54 PM

Post# of 403658
My concerns within this space are reflected in news like this today:

https://endpts.com/achaogens-bankruptcy-and-going-out-of-business-sale-offer-a-grim-cautionary-tale-for-the-future-of-antibiotic-development/


'The lights are winking out at Achaogen, offering another cautionary tale that will make it even less likely we’ll see new companies come along to develop antibiotics — even as drug-resistant strains of bacteria pose a rising threat to the world’s population.'

'On Monday, the South San Francisco-based biotech filed for Chapter 11 bankruptcy, setting up an auction for its assets, which primarily center on their recently approved antibiotic Zemdri — which boasted an ability to tackle carbapenem-resistant Enterobacteriaceae, the CDC’s “nightmare bacteria.” Its stock $AKAO, already deep in penny land, fell 68% to 16 cents a share, which underscores just what investors think that’s worth now.'


Have a read through the article. It's insightful

Author Copyright is: John Carroll from Endpoints News
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News